Gufic Biosciences Reports Rs. 6,165.45 Lakh Profit Before Tax for H1 FY2026-27, Appoints Dr. Reeta Shah as Independent Director
Company posts Rs. 6,165.45 lakh profit before tax for half year ended September 30, 2026, and names Dr. Reeta Shah as Additional Independent Director effective December 1, 2026, subject to shareholder approval
Gufic Biosciences Limited announced unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a profit before tax of Rs. 6,165.45 lakh for the half year. The company also approved the appointment of Dr. Reeta Shah as an Additional Non-Executive Independent Director for a 5-year term starting December 1, 2026, subject to shareholder approval.
Gufic Biosciences Limited
Financial Results
Gufic Biosciences Limited declared unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, posting a profit before tax of Rs. 6,165.45 lakh for the half year period. The company's Board of Directors also approved the appointment of Dr. Reeta Shah as an Additional Non-Executive Independent Director for five years, starting December 1, 2026, pending shareholder approval.
For the half year ended September 30, 2026, Gufic Biosciences recorded standalone revenue from operations of Rs. 54,921.95 lakh and consolidated revenue of Rs. 54,909.10 lakh.
The standalone profit before tax for the half year stood at Rs. 6,165.45 lakh, while consolidated profit before tax was Rs. 6,148.68 lakh.
Net profit for the half year was Rs. 4,594.91 lakh on a standalone basis and Rs. 4,578.17 lakh consolidated.
The Board approved the appointment of Dr. Reeta Shah as an Additional Non-Executive Independent Director for a term of five consecutive years starting December 1, 2026, subject to shareholder approval.
The Board meeting was held on November 14, 2026, starting at 5:00 p.m. and concluding at 6:35 p.m.
Highlights
- Unaudited standalone and consolidated financial results approved for quarter and half year ended September 30, 2026.
- Standalone revenue from operations for H1 2026: Rs. 54,921.95 lakh; consolidated: Rs. 54,909.10 lakh.
- Profit before tax for H1 2026: Rs. 6,165.45 lakh (standalone), Rs. 6,148.68 lakh (consolidated).
- Net profit for H1 2026: Rs. 4,594.91 lakh (standalone), Rs. 4,578.17 lakh (consolidated).
- Appointment of Dr. Reeta Shah as Additional Non-Executive Independent Director for five years from December 1, 2026, subject to shareholder approval.
- Dr. Reeta Shah is not debarred from holding office by SEBI or any authority.
Key Data Snapshot
What happened
- Gufic Biosciences released unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
- The company recorded a profit before tax of Rs. 6,165.45 lakh for the half year on a standalone basis.
- The Board approved the appointment of Dr. Reeta Shah as an Additional Non-Executive Independent Director for a period of five years starting December 1, 2026, subject to shareholder approval.
Key details
- Standalone revenue from operations for H1 2026 was Rs. 54,921.95 lakh, while consolidated revenue was Rs. 54,909.10 lakh.
- Net profit for the half year was Rs. 4,594.91 lakh standalone and Rs. 4,578.17 lakh consolidated.
- Dr. Reeta Shah is not barred by SEBI or any authority from holding the office of director.
- The Board meeting was held on November 14, 2026, and lasted from 5:00 p.m. to 6:35 p.m.
Regulatory and governance context
- The financial results were prepared under Regulation 33 of SEBI Listing Regulations and duly reviewed by a limited review report.
- Appointment of Dr. Reeta Shah aligns with provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Shareholder approval is required for the appointment of Dr. Reeta Shah as an independent director.
Highlights
- Unaudited standalone and consolidated financial results approved for quarter and half year ended September 30, 2026.
- Standalone revenue from operations for H1 2026: Rs. 54,921.95 lakh; consolidated: Rs. 54,909.10 lakh.
- Profit before tax for H1 2026: Rs. 6,165.45 lakh (standalone), Rs. 6,148.68 lakh (consolidated).
- Net profit for H1 2026: Rs. 4,594.91 lakh (standalone), Rs. 4,578.17 lakh (consolidated).
- Appointment of Dr. Reeta Shah as Additional Non-Executive Independent Director for five years from December 1, 2026, subject to shareholder approval.
- Dr. Reeta Shah is not debarred from holding office by SEBI or any authority.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Regulation 33 of SEBI Listing Regulations
- SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
Source Information
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Balaji Telefilms Announces Unaudited Q2 and H1 Financial Results for September 30, 2026
Balaji Telefilms Limited has released its unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2026. The results were reviewed by the company's independent auditor Deloitte Haskins & Sells LLP and include financial data from its subsidiaries Balaji Motion Pictures Limited and Ding Infinity Private Limited.
Read Full StoryGenesys International Announces Q2 FY2027 Unaudited Financials and Grants 3.65 Lakh Employee Stock Options at Discounted Prices
Genesys International Corporation Limited disclosed its unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026, reporting a profit before tax of Rs.727.84 lakh in the quarter. The company also approved the grant of 3,65,000 employee stock options under its 2022 ESOP scheme, with exercise prices between Rs.70 to Rs.100, discounted significantly from the previous day's NSE closing price.
Read Full StoryShri Ram Apartment Development Co Ltd Submits Incomplete Filing with No Financial or Corporate Data
Shri Ram Apartment Development Co Ltd submitted a filing to BSE that only references annexures but does not contain any financial, corporate, or transactional information.
Read Full Story